文献速递慢性静脉疾病

前副大隐静脉与大隐静脉疾病严重程度及治疗结局比较

Severity of disease and treatment outcomes of anterior accessory great saphenous veins compared with the great saphenous vein.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2021-08-24

本研究回顾性分析2015-2018年数据,比较孤立性前副大隐静脉(AAGSV)反流与大隐静脉(GSV)反流患者接受消融或消融+静脉切除术后的结局。AAGSV组与GSV组在rVCSS评分上无差异,但单独消融的AAGSV患者6个月时CIVIQ20评分回升至术前水平,联合静脉切除术则消失此现象。提示AAGSV患者需同时处理属支静脉曲张。

要点

  • AAGSV与GSV反流患者消融后rVCSS评分改善相似。
  • 单独消融的AAGSV患者6个月CIVIQ20评分回升至术前水平。
  • 联合静脉切除术可消除AAGSV患者生活质量评分回升。

核心结论

  • 有症状AAGSV的腔内治疗结局与GSV相似,但单独消融后6个月生活质量评分回升至术前水平。
  • AAGSV患者接受消融时需同时处理相关属支静脉曲张以达到与GSV相似结局。

研究设计与样本

  • 孤立性AAGSV反流91例/103条肢体,孤立性GSV反流7704例/10371条肢体;比较单独消融与消融+静脉切除术结局。
  • 术后1个月和6个月使用修订版静脉临床严重程度评分(rVCSS)和20项慢性静脉功能不全生活质量问卷(CIVIQ20)评估。

主要发现

  • 单独消融组:AAGSV(57例/61条肢体)与GSV(5349例/7191条肢体)术前rVCSS 7.0±2.0 vs 6.8±2.8(P=.99),1个月4.0±2.4 vs 3.9±2.8(P=.99),6个月3.9±2.6 vs 3.9±2.9(P=.55)。
  • 消融+静脉切除术组:AAGSV(34例/42条肢体)与GSV(1848例/2491条肢体)rVCSS结果相似。
  • CIVIQ20评分:AAGSV与GSV术前53.3±19.6 vs 50.6±18.8(P=.43),1个月37.2±17.6 vs 35.7±15.9(P=.91),6个月41.3±21.7 vs 35.1±15.7(P=.36)。
  • 组内术后1个月和6个月评分均改善(P≤.02);但单独消融的AAGSV患者6个月CIVIQ20较1个月略升高,与GSV术前评分无差异(P=.07)。
  • 联合静脉切除术时,6个月CIVIQ20组间相似(P=.72);AAGSV与GSV组平均消融次数1.24±0.44 vs 1.35±0.49(P=.15)。

临床怎么用

  • 对有症状AAGSV反流患者,消融治疗应联合静脉切除术处理相关属支静脉曲张。
  • 单独消融AAGSV可能不足以维持生活质量改善,需谨慎评估其有效性。

局限性

  • 回顾性分析电子病历数据,可能存在选择偏倚和信息偏倚。
  • AAGSV组样本量较小(91例/103条肢体),可能影响统计效能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Endovenous therapies are currently the standard of care for the treatment of patients with symptomatic great saphenous vein (GSV) reflux. The effectiveness and long-term outcomes of these therapies for anterior accessory great saphenous veins (AAGSVs) are poorly defined. The objective of this investigation is to determine treatment outcomes in patients with symptomatic AAGSV reflux compared with patients with symptomatic GSV reflux. METHODS: Data were prospectively collected in the Center for Vein Restoration's electronic medical record system (NexGen Healthcare Information System, Irvine, Calif) and retrospectively analyzed. Treatment outcomes after a standalone ablation and ablation + phlebectomy were compared in patients with isolated AAGSV and GSV reflux. Treatment outcomes were assessed at 1 month and 6 months postprocedure using the revised Venous Clinical Severity Score (rVCSS) and the 20-item Chronic Venous Insufficiency Quality-of-Life Questionnaire (CIVIQ20) survey for quality of life. Medical and surgical comorbidities, Clinical-Etiological-Anatomical-Pathophysiological classification, body mass index, gender, race, and the average number of procedures performed were all analyzed. RESULTS: From January 2015 to December 2018, 31,186 patients and 49,193 limbs were assessed. Of these, 91 patients/103 limbs had isolated AAGSV reflux, and 7704 patients/10,371 limbs had isolated GSV reflux. There were 95% and 75% women in the isolated AAGSV and GSV groups, respectively (P ≤ .001). For the ablation-only patients, AAGSV (n = 57 patients/61 limbs) and GSV (n = 5349 patients/7191 limbs), there were no differences in preintervention (7.0 ± 2.0 vs 6.8 ± 2.8, P = .99), 1-month (4.0 ± 2.4 vs 3.9 ± 2.8, P = .99), and 6-month (3.9 ± 2.6 vs 3.9 ± 2.9, P = .55) rVCSS scores. Similar results were observed when ablations and phlebectomies were performed (AAGSV [n = 34 patients/42 limbs] and GSV [n = 1848 patients/2491 limbs]). CIVIQ20 scores for patients with isolated AAGSV and GSV were 53.3 ± 19.6 vs 50.6 ± 18.8 (P = .43) preintervention, 37.2 ± 17.6 vs 35.7 ± 15.9 (P = .91) at 1 month, and 41.3 ± 21.7 vs 35.1 ± 15.7 (P = .36) at 6 months, respectively. Postprocedure scores within groups improved at 1 and 6 months (P ≤ .02); however, 6-month AAGSV CIVIQ20 scores after an ablation increased slightly compared with 1-month scores and were not different to preintervention GSV scores (P = .07). When phlebectomies were performed with ablations, 6-month CIVIQ20 scores were similar between groups (P = .72). There was no difference in the average number of ablations in patients with phlebectomies in the AAGSV or GSV group (1.24 ± 0.44 vs 1.35 ± 0.49, P = .15). CONCLUSIONS: Endovenous therapies for the treatment of symptomatic AAGSVs demonstrate similar outcomes to patients with symptomatic GSV reflux. For standalone ablations, the rVCSS scores are similar between the groups; however, CIVIQ20 scores increase to preintervention levels in standalone ablation AAGSV patients at 6 months. This increase disappears when phlebectomies are performed with ablations. Based on these data, patients with symptomatic AAGSV treated with ablation also require treatment of the associated tributaries (varicosities) to achieve similar outcomes to patients with GSV, and this calls into question the effectiveness of ablation for isolated AAGSV reflux.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Deol ZK, Lakhanpal S, Pappas PJ, et al. Severity of disease and treatment outcomes of anterior accessory great saphenous veins compared with the great saphenous vein. J Vasc Surg Venous Lymphat Disord. 2021. PMID: 34438092. doi:10.1016/j.jvsv.2021.08.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。